Sabag Mark 4

What Happened

Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries (TEVA), had 15,723 restricted share units (RSUs) vest on March 5, 2026 and those units were converted/exercised into 15,723 ordinary shares. The Form 4 shows the acquisition as an exercise/conversion of a derivative (code M) and a corresponding disposition at $0.00 (no cash proceeds): this reflects share settlement of RSUs rather than an open-market sale.

Key Details

• Transaction date: March 5, 2026 (reported on Form 4 filed March 9, 2026 — timely filing).
• Shares acquired: 15,723 ordinary shares via conversion of RSUs; disposition entry shows $0.00 (no sale proceeds).
• Shares owned after transaction: Not specified in the filing.
• Footnotes of note:
  • F2: Each restricted share unit represents a contingent right to receive one ordinary share (or, at the committee’s option, cash).
  • F3: These RSUs were granted March 5, 2025; 15,723 vested on March 5, 2026 with additional tranches vesting in 2027–2029.
  • F1: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share).
• Filing timeliness: Reported within the SEC’s reporting window (filed March 9 for a March 5 transaction).

Context

This was a vesting/settlement of previously granted RSUs (an award converting to shares), not an open-market purchase or sale. Such conversions are routine compensation events and do not by themselves signal a buy or sell decision by the insider. The filing does not show any immediate sale of the shares or any tax-withholding share disposition details.